The DOI matches its Crossref record; 112 of the 112 references it cites were found in a registry or an index.
Metastatic osteosarcoma: a challenging multidisciplinary treatment
Abstract
Osteosarcoma is the most common malignant bone tumor, currently treated with pre-and postoperative chemotherapy in association with the surgical removal of the tumor. About 15-20% of patients have evidence of metastases at diagnosis, mostly in the lungs. Patients with metastatic disease still have a very poor prognosis, with approximately 20-30% of long-term survivors, as compared with 65-70% of patients with localized disease. The optimum management of these patients has not been standardized yet due to several patterns of metastatic disease harboring different prognosis. Complete surgical resection of all sites of disease is mandatory and predictive of survival. Patients with multiple sites of disease not amenable to complete surgery removal should be considered for innovative therapeutic approaches because of poor prognosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bielack, S. S., Kempf-Bielack, B., Delling, G., Exner, G. U., Flege, S., Helmke, K., Kotz, R., Salzer-Kuntschik, M., Werner, M., Winkelmann, W., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.3.776 · Cited by 2,393 · cited 3×
“OS commonly occurs in long bones of the extremities such as the distal femur (42% of cases), the proximal tibia (19%), and the proximal humerus (10%) [7].”
BackgroundThe Epidemiology of Osteosarcoma
Ottaviani, G., & Jaffe, N. (2009) · Cancer Treatment and Research · doi:10.1007/978-1-4419-0284-9_1 · Cited by 1,786
Translational biology of osteosarcoma
Kansara, M., Teng, M. W., Smyth, M. J., & Thomas, D. M. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3838 · Cited by 1,294 · cited 2×
“The mammalian target of rapamycin (mTOR) pathway is very important in bone biology and considered an attractive therapeutic target in several tumors, including OS [15,37,38,97].”
BackgroundOsteosarcoma treatment – Where do we stand? A state of the art review
Luetke, A., Meyers, P. A., Lewis, I., & Juergens, H. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.11.006 · Cited by 1,234
Rosen, G., Caparros, B., Huvos, A. G., Kosloff, C., Nirenberg, A., Cacavio, A., Marcove, R. C., Lane, J. M., Mehta, B., & Urban, C. (1982) · Cancer · doi:10.1002/1097-0142(19820315)49:6<1221::aid-cncr2820490625>3.0.co;2-e · Cited by 1,090
Childhood cancer survival in Europe 1999–2007: results of EUROCARE-5—a population-based study
Gatta, G., Botta, L., Rossi, S., Aareleid, T., Bielska-Lasota, M., Clavel, J., Dimitrova, N., Jakab, Z., Kaatsch, P., Lacour, B., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70548-5 · Cited by 1,075
Kager, L., Zoubek, A., Pötschger, U., Kastner, U., Flege, S., Kempf-Bielack, B., Branscheid, D., Kotz, R., Salzer-Kuntschik, M., Winkelmann, W., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.08.132 · Cited by 934
Meyers, P. A., Schwartz, C. L., Krailo, M. D., Healey, J. H., Bernstein, M. L., Betcher, D., Ferguson, W. S., Gebhardt, M. C., Goorin, A. M., Harris, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.14.0095 · Cited by 752
Recurrent Somatic Structural Variations Contribute to Tumorigenesis in Pediatric Osteosarcoma
Chen, X., Bahrami, A., Pappo, A., Easton, J., Dalton, J., Hedlund, E., Ellison, D., Shurtleff, S., Wu, G., Wei, L., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.03.003 · Cited by 752
Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience.
Meyers, P. A., Heller, G., Healey, J., Huvos, A., Lane, J., Marcove, R., Applewhite, A., Vlamis, V, & Rosen, G. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.1.5 · Cited by 678
Biology and Therapeutic Advances for Pediatric Osteosarcoma
Marina, N., Gebhardt, M., Teot, L., & Gorlick, R. (2004) · The Oncologist · doi:10.1634/theoncologist.9-4-422 · Cited by 671
Kempf-Bielack, B., Bielack, S. S., Jürgens, H., Branscheid, D., Berdel, W. E., Exner, G. U., Göbel, U., Helmke, K., Jundt, G., Kabisch, H., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.063 · Cited by 643
Primary bone osteosarcoma in the pediatric age: State of the art
Longhi, A., Errani, C., De Paolis, M., Mercuri, M., & Bacci, G. (2006) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2006.05.005 · Cited by 631
Bacci, G., Longhi, A., Versari, M., Mercuri, M., Briccoli, A., & Picci, P. (2006) · Cancer · doi:10.1002/cncr.21724 · Cited by 569
Osteosarcoma: a review of diagnosis, management, and treatment strategies.
Geller, D. S., & Gorlick, R. G. (2010) · PubMed · Cited by 475
Winkler, K., Beron, G., Delling, G., Heise, U., Kabisch, H., Purfürst, C., Berger, J., Ritter, J., Jürgens, H., & Gerein, V (1988) · Journal of Clinical Oncology · doi:10.1200/jco.1988.6.2.329 · Cited by 459
Bielack, S. S., Smeland, S., Whelan, J. S., Marina, N., Jovic, G., Hook, J. M., Krailo, M. D., Gebhardt, M., Pápai, Z., Meyer, J., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.0734 · Cited by 422
Osteogenic sarcoma with clinically detectable metastasis at initial presentation.
Meyers, P. A., Heller, G., Healey, J. H., Huvos, A., Applewhite, A., Sun, M., & LaQuaglia, M. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.3.449 · Cited by 390
Grignani, G., Palmerini, E., Dileo, P., Asaftei, S. D., D’Ambrosio, L., Pignochino, Y., Mercuri, M., Picci, P., Fagioli, F., Casali, P. G., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mdr151 · Cited by 359
FGFR Genetic Alterations Predict for Sensitivity to NVP-BGJ398, a Selective Pan-FGFR Inhibitor
Guagnano, V., Kauffmann, A., Wöhrle, S., Stamm, C., Ito, M., Barys, L., Pornon, A., Yao, Y., Li, F., Zhang, Y., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0210 · Cited by 347
Lewis, I. J., Nooij, M. A., Whelan, J., Sydes, M. R., Grimer, R., Hogendoorn, P. C. W., Memon, M. A., Weeden, S., Uscinska, B. M., van Glabbeke, M., et al. (2007) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djk015 · Cited by 346
Fuchs, N., Bielack, S. S., Epler, D., Bieling, P., Delling, G., Körholz, D., Graf, N., Heise, U., Jürgens, H., Kotz, R., et al. (1998) · Annals of Oncology · doi:10.1023/a:1008391103132 · Cited by 343
Osteosarcoma of the Pelvis: Experience of the Cooperative Osteosarcoma Study Group
Ozaki, T., Flege, S., Kevric, M., Lindner, N., Maas, R., Delling, G., Schwarz, R., von Hochstetter, A. R., Salzer-Kuntschik, M., Berdel, W. E., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.01.142 · Cited by 342
Grignani, G., Palmerini, E., Ferraresi, V., D'Ambrosio, L., Bertulli, R., Asaftei, S. D., Tamburini, A., Pignochino, Y., Sangiolo, D., Marchesi, E., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71136-2 · Cited by 340
Whelan, J. S., Bielack, S. S., Marina, N., Smeland, S., Jovic, G., Hook, J. M., Krailo, M., Anninga, J., Butterfass-Bahloul, T., Böhling, T., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdu526 · Cited by 333
Miser, J. S., Kinsella, T. J., Triche, T. J., Tsokos, M., Jarosinski, P., Forquer, R., Wesley, R., & Magrath, I. (1987) · Journal of Clinical Oncology · doi:10.1200/jco.1987.5.8.1191 · Cited by 317
Osteosarcoma treatment: state of the art
Ta, H. T., Dass, C. R., Choong, P. F. M., & Dunstan, D. E. (2009) · Cancer and Metastasis Reviews · doi:10.1007/s10555-009-9186-7 · Cited by 314
Meyers, P. A., Gorlick, R., Heller, G., Casper, E., Lane, J., Huvos, A. G., & Healey, J. H. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.7.2452 · Cited by 294
Mialou, V., Philip, T., Kalifa, C., Perol, D., Gentet, J., Marec‐Berard, P., Pacquement, H., Chastagner, P., Defaschelles, A., & Hartmann, O. (2005) · Cancer · doi:10.1002/cncr.21263 · Cited by 286
Stiller, C. A., Bielack, S. S., Jundt, G., & Steliarova-Foucher, E. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.05.015 · Cited by 283
Therapy for Osteosarcoma: Where Do We Go From Here?
Chou, A. J., Geller, D. S., & Gorlick, R. (2008) · Pediatric Drugs · doi:10.2165/00148581-200810050-00005 · Cited by 274
Picci, P., Bacci, G., Campanacci, M., Gasparini, M., Pilotti, S., Cerasoli, S., Bertoni, F., Guerra, A., Capanna, R., Albisinni, U., et al. (1985) · Cancer · doi:10.1002/1097-0142(19851001)56:7<1515::aid-cncr2820560707>3.0.co;2-6 · Cited by 274
New targets and approaches in osteosarcoma
Gill, J., Ahluwalia, M. K., Geller, D., & Gorlick, R. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.09.003 · Cited by 273
Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
(2014) · Annals of Oncology · doi:10.1093/annonc/mdu256 · Cited by 263
Chawla, S. P., Staddon, A. P., Baker, L. H., Schuetze, S. M., Tolcher, A. W., D'Amato, G. Z., Blay, J.-Y., Mita, M. M., Sankhala, K. K., Berk, L., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.6329 · Cited by 246
Chou, A. J., Kleinerman, E. S., Krailo, M. D., Chen, Z., Betcher, D. L., Healey, J. H., Conrad, E. U., Nieder, M. L., Weiner, M. A., Wells, R. J., et al. (2009) · Cancer · doi:10.1002/cncr.24566 · Cited by 245
Demetri, G. D., Chawla, S. P., Ray-Coquard, I., Le Cesne, A., Staddon, A. P., Milhem, M. M., Penel, N., Riedel, R. F., Bui-Nguyen, B., Cranmer, L. D., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.5766 · Cited by 245
Children's Oncology Group's 2013 blueprint for research: Bone tumors
Gorlick, R., Janeway, K., Lessnick, S., Randall, R. L., Marina, N., & on behalf of the COG Bone Tumor Committee (2013) · Pediatric Blood & Cancer · doi:10.1002/pbc.24429 · Cited by 226
Goorin, A. M., Harris, M. B., Bernstein, M. L., Ferguson, W., Devidas, M., Siegal, G. P., Gebhardt, M. C., Schwartz, C. L., Link, M. P., & Grier, H. E. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.2.426 · Cited by 223
Adjuvant and neoadjuvant combination chemotherapy for osteogenic sarcoma
Ferrari, S., & Palmerini, E. (2007) · Current Opinion in Oncology · doi:10.1097/cco.0b013e328122d73f · Cited by 219
Rapamycin Inhibits Ezrin-Mediated Metastatic Behavior in a Murine Model of Osteosarcoma
Wan, X., Mendoza, A., Khanna, C., & Helman, L. J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3135 · Cited by 216
Anderson, P. M., Wiseman, G. A., Dispenzieri, A. A., Arndt, C. A. S., Hartmann, L. C., Smithson, W. A., Mullan, B. P., & Bruland, Ø. S. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.1.189 · Cited by 214
Briccoli, A., Rocca, M., Salone, M., Guzzardella, G. A., Balladelli, A., & Bacci, G. (2010) · Surgical Oncology · doi:10.1016/j.suronc.2009.05.002 · Cited by 210
Bacci, G., Rocca, M., Salone, M., Balladelli, A., Ferrari, S., Palmerini, E., Forni, C., & Briccoli, A. (2008) · Journal of Surgical Oncology · doi:10.1002/jso.21140 · Cited by 203 · cited 1×
“gery of the primary site [74], even though these patients have a worse prognosis than those with metachronous metastatic spread [75,76].”
BackgroundEnhanced T-Cell Immunity to Osteosarcoma Through Antibody Blockade of PD-1/PD-L1 Interactions
Lussier, D. M., O’Neill, L., Nieves, L. M., McAfee, M. S., Holechek, S. A., Collins, A. W., Dickman, P., Jacobsen, J., Hingorani, P., & Blattman, J. N. (2015) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000065 · Cited by 197 · cited 1×
“A recent preclinical study in a mouse model provided evidence that blocking PD-1 or PD-L1 interactions can inhibit in vivo OS cell growth [122].”
BackgroundPrognostic factors and outcomes for osteosarcoma: An international collaboration
Pakos, E. E., Nearchou, A. D., Grimer, R. J., Koumoullis, H. D., Abudu, A., Bramer, J. A. M., Jeys, L. M., Franchi, A., Scoccianti, G., Campanacci, D., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2009.03.005 · Cited by 193
Ferrari, S., Ruggieri, P., Cefalo, G., Tamburini, A., Capanna, R., Fagioli, F., Comandone, A., Bertulli, R., Bisogno, G., Palmerini, E., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.4420 · Cited by 192
Proton‐based radiotherapy for unresectable or incompletely resected osteosarcoma
Ciernik, I. F., Niemierko, A., Harmon, D. C., Kobayashi, W., Chen, Y., Yock, T. I., Ebb, D. H., Choy, E., Raskin, K. A., Liebsch, N., et al. (2011) · Cancer · doi:10.1002/cncr.26037 · Cited by 191 · cited 1×
“In particular, proton and carbon ion beams [87] have the advantage of a superior biological dose distribution”
BackgroundBacci, G., Briccoli, A., Rocca, M., Ferrari, S., Donati, D., Longhi, A., Bertoni, F., Bacchini, P., Giacomini, S., Forni, C., et al. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg286 · Cited by 187
Treatment of metastatic osteosarcoma at diagnosis: a Pediatric Oncology Group Study.
Harris, M. B., Gieser, P., Goorin, A. M., Ayala, A., Shochat, S. J., Ferguson, W. S., Holbrook, T., & Link, M. P. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.11.3641 · Cited by 185
Pignochino, Y., Grignani, G., Cavalloni, G., Motta, M., Tapparo, M., Bruno, S., Bottos, A., Gammaitoni, L., Migliardi, G., Camussi, G., et al. (2009) · Molecular Cancer · doi:10.1186/1476-4598-8-118 · Cited by 180
Toward a Drug Development Path That Targets Metastatic Progression in Osteosarcoma
Khanna, C., Fan, T. M., Gorlick, R., Helman, L. J., Kleinerman, E. S., Adamson, P. C., Houghton, P. J., Tap, W. D., Welch, D. R., Steeg, P. S., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2574 · Cited by 178
Miller, B. J., Cram, P., Lynch, C. F., & Buckwalter, J. A. (2013) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.l.01189 · Cited by 177
Harting, M. T., Blakely, M. L., Jaffe, N., Cox, C. S., Hayes-Jordan, A., Benjamin, R. S., Raymond, A. K., Andrassy, R. J., & Lally, K. P. (2006) · Journal of Pediatric Surgery · doi:10.1016/j.jpedsurg.2005.10.089 · Cited by 174
Ganglioside GD2 as a therapeutic target for antibody‐mediated therapy in patients with osteosarcoma
Roth, M., Linkowski, M., Tarim, J., Piperdi, S., Sowers, R., Geller, D., Gill, J., & Gorlick, R. (2014) · Cancer · doi:10.1002/cncr.28461 · Cited by 167
Le Deley, M.-C., Guinebretière, J.-M., Gentet, J.-C., Pacquement, H., Pichon, F., Marec-Bérard, P., Entz-Werlé, N., Schmitt, C., Brugières, L., Vanel, D., et al. (2007) · European Journal of Cancer · doi:10.1016/j.ejca.2006.10.023 · Cited by 162
Impact of carbon ion radiotherapy for unresectable osteosarcoma of the trunk
Matsunobu, A., Imai, R., Kamada, T., Imaizumi, T., Tsuji, H., Tsujii, H., Shioyama, Y., Honda, H., Tatezaki, S., & for the Working Group for Bone and Soft Tissue Sarcomas (2012) · Cancer · doi:10.1002/cncr.27451 · Cited by 158 · cited 1×
“with OS of the trunk traded with carbon ion RT [88].”
MethodHoughton, P. J., Morton, C. L., Kolb, E. A., Gorlick, R., Lock, R., Carol, H., Reynolds, C. P., Maris, J. M., Keir, S. T., Billups, C. A., et al. (2008) · Pediatric Blood & Cancer · doi:10.1002/pbc.21296 · Cited by 158
Bruland, Ø. S., & Pihl, A. (1997) · European Journal of Cancer · doi:10.1016/s0959-8049(97)00252-9 · Cited by 155
Recurrent osteosarcoma with a single pulmonary metastasis: a multi-institutional review
Daw, N. C., Chou, A. J., Jaffe, N., Rao, B. N., Billups, C. A., Galindo, C. R., Meyers, P. A., & Huh, W. W. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.585 · Cited by 151
Neoadjuvant Chemotherapy and Local Radiotherapy for High-Grade Osteosarcoma of the Extremities
Machak, G. N., Si, T., Solovyev, Y. N., Sinyukov, P. A., Ivanov, S. M., Кочергина, Н. В., Ryjkov, A. D., Тепляков, В. В., Bokhyan, B. Y., & Glebovskaya, V. V. (2003) · Mayo Clinic Proceedings · doi:10.4065/78.2.147 · Cited by 149
Pulmonary metastasectomy: what is the practice and where is the evidence for effectiveness?: Table 1
Treasure, T., Milošević, M., Fiorentino, F., & Macbeth, F. R. (2014) · Thorax · doi:10.1136/thoraxjnl-2013-204528 · Cited by 144
Akiyama, T., Dass, C. R., & Choong, P. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0530 · Cited by 139
Stature of young people with malignant bone tumors
Cotterill, S. J., Wright, C. M., Pearce, M. S., & Craft, A. W. (2003) · Pediatric Blood & Cancer · doi:10.1002/pbc.10437 · Cited by 129
Osteosarcoma Multidisciplinary Approach to the Management from the Pathologist’s Perspective
Raymond, A. K., & Jaffe, N. (2009) · Cancer treatment and research · doi:10.1007/978-1-4419-0284-9_4 · Cited by 125
Prognosis for patients who have osteosarcoma with skip metastasis.
Wuisman, P. I. J. M., & Enneking, W. F. (1990) · Journal of Bone and Joint Surgery · doi:10.2106/00004623-199072010-00010 · Cited by 122
Osteogenic sarcoma of the extremity with detectable lung metastases at presentation
Bacci, G., Mercuri, M., Briccoli, A., Ferrari, S., Bertoni, F., Donati, D. M., Monti, C., Zanoni, A., Forni, C., & Manfrini, M. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19970115)79:2<245::aid-cncr7>3.0.co;2-j · Cited by 122
Improved prognosis of children with osteosarcoma metastatic to the lung(s) at the time of diagnosis
Marina, N. M., Pratt, C. B., Rao, B. N., Shema, S. J., & Meyer, W. H. (1992) · Cancer · Cited by 118
Efficacy of Liposomal Muramyl Tripeptide (CGP 19835A) in the Treatment of Relapsed Osteosarcoma
Kleinerman, E. S., Gano, J. B., Johnston, D. A., Benjamin, R. S., & Jaffe, N. (1995) · American Journal of Clinical Oncology · doi:10.1097/00000421-199504000-00001 · Cited by 116
Daw, N. C., Billups, C. A., Galindo, C. R., McCarville, M. B., Rao, B. N., Cain, A. M., Jenkins, J. J., Neel, M. D., & Meyer, W. H. (2005) · Cancer · doi:10.1002/cncr.21626 · Cited by 112
Pignochino, Y., Dell’Aglio, C., Basiricò, M., Capozzi, F., Soster, M., Marchiò, S., Bruno, S., Gammaitoni, L., Sangiolo, D., Torchiaro, E., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2293 · Cited by 112
Bacci, G., Mercuri, M., Briccoli, A., Ferrari, S., Bertoni, F., Donati, D. M., Monti, C., Zanoni, A., Forni, C., & Manfrini, M. (1997) · PubMed · Cited by 109
Recent advances in the management of osteosarcoma and forthcoming therapeutic strategies
Lamoureux, F., Trichet, V., Chipoy, C., Blanchard, F., Gouin, F., & Rédiní, F. (2007) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.7.2.169 · Cited by 106
International Collaboration is Feasible in Trials for Rare Conditions: The EURAMOS Experience
Marina, N. M., Bielack, S., Whelan, J. S., Smeland, S., Krailo, M., Sydes, M. R., Butterfaß‐Bahloul, T., Calaminus, G., & Bernstein, M. L. (2009) · Cancer treatment and research · doi:10.1007/978-1-4419-0284-9_18 · Cited by 102
Moriceau, G., Ory, B., Mitrofan, L. M., Riganti, C., Blanchard, F., Brion, R., Charrier, C., Battaglia, S., Pilet, P., Denis, M. G., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0578 · Cited by 101
Emerging drugs for high-grade osteosarcoma
Hattinger, C. M., Pasello, M., Ferrari, S., Picci, P., & Serra, M. (2010) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2010.505603 · Cited by 99
Genome-wide analyses on high-grade osteosarcoma: Making sense of a genomically most unstable tumor
Kuijjer, M. L., Hogendoorn, P. C. W., & Cleton-Jansen, A. (2013) · International Journal of Cancer · doi:10.1002/ijc.28124 · Cited by 90
Novel therapeutic agents for osteosarcoma
O’Day, K., & Gorlick, R. G. (2009) · Expert Review of Anticancer Therapy · doi:10.1586/era.09.7 · Cited by 89
High-dose ifosfamide in advanced osteosarcoma.
Marti, C., Kröner, P. T., Remagen, W., Berchtold, W., Cserhati, M., & Varini, M. (1985) · PubMed · Cited by 89
Kolb, E. A., Gorlick, R. G., Reynolds, C. P., Kang, M. H., Carol, H., Lock, R. B., Keir, S. T., Maris, J. M., Billups, C. A., DesJardins, C., et al. (2013) · Pediatric Blood & Cancer · doi:10.1002/pbc.24517 · Cited by 86
Gemcitabine Radiosensitization after High-Dose Samarium for Osteoblastic Osteosarcoma
Anderson, P. M., Wiseman, G. A., Erlandson, L., Rodriguez, V., Trotz, B. A., Dubansky, S. A., & Albritton, K. H. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0628 · Cited by 82
Correlation between clinical outcome and growth factor pathway expression in osteogenic sarcoma
Abdeen, A. R., Chou, A. J., Healey, J. H., Khanna, C., Osborne, T. S., Hewitt, S. M., Kim, M., Wang, D., Moody, K. M., & Gorlick, R. G. (2009) · Cancer · doi:10.1002/cncr.24562 · Cited by 80
Labrinidis, A., Hay, S. J., Liapis, V., Ponomarev, V., Findlay, D. M., & Evdokiou, A. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1616 · Cited by 79
Surgical Intervention for Pulmonary Metastases
Pfannschmidt, J., Egerer, G., Bischof, M., Thomas, M., & Dienemann, H. (2012) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2012.0645 · Cited by 72
Beristain, A. G., Narala, S., Grappa, M. A. D., & Khokha, R. (2012) · Journal of Cell Science · doi:10.1242/jcs.094029 · Cited by 69
Osteosarcoma Lung Metastases Detection and Principles of Multimodal Therapy
Carrle, D., & Bielack, S. (2009) · Cancer treatment and research · doi:10.1007/978-1-4419-0284-9_8 · Cited by 65
Expression of programmed death 1 is correlated with progression of osteosarcoma
Zheng, W., Xiao, H. P., Liu, H., & Zhou, Y. (2014) · Apmis · doi:10.1111/apm.12311 · Cited by 60
Nab-Paclitaxel Is an Active Drug in Preclinical Model of Pediatric Solid Tumors
Zhang, L., Marrano, P. M., Kumar, S., Leadley, M., Elias, E., Thorner, P. S., & Baruchel, S. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1485 · Cited by 60
Bacci, G., Longhi, A., Bertoni, F., Briccoli, A., Versari, M., Pignotti, E., & Picci, P. (2006) · Acta Orthopaedica · doi:10.1080/17453670610013268 · Cited by 59
Song, B. S., Seo, J., Kim, D. H., Lim, J. S., Yoo, J. Y., & Lee, J. A. (2014) · Pediatric Blood & Cancer · doi:10.1002/pbc.25035 · Cited by 57
Longhi, A., Fabbri, N., Donati, D. M., et al. (2001) · Journal of Chemotherapy · doi:10.1179/joc.2001.13.3.324 · Cited by 54
Boye, K., del Prever, A. B., Eriksson, M., Sæter, G., Tienghi, A., Lindholm, P., Fagioli, F., Skjeldal, S., Ferrari, S., & Hall, K. S. (2013) · Pediatric Blood & Cancer · doi:10.1002/pbc.24868 · Cited by 52
Voûte, P. A., Souhami, R. L., Nooij, M. A., Somers, R., Cortés-Funes, H., van der Eijken, J. W., Pringle, J. A. S., Hogendoorn, P. C. W., Kirkpatrick, A., Uscinska, B., et al. (1999) · Annals of Oncology · doi:10.1023/a:1008361612767 · Cited by 48
Radiotherapy in the Treatment of Primary Osteosarcoma – a Single Center Experience
Oertel, S., Blattmann, C., Rieken, S., Jensen, A., Combs, S. E., Huber, P. E., Bischof, M., Kulozik, A. E., Debus, J., & Schulz–Ertner, D. (2010) · Tumori Journal · doi:10.1177/030089161009600411 · Cited by 48
Pazopanib in metastatic osteosarcoma: Significant clinical response in three consecutive patients
Safwat, A., Boysen, A. K., Lücke, A. O., & Rossen, P. B. (2014) · Acta Oncologica · doi:10.3109/0284186x.2014.948062 · Cited by 47
Bacci, G., Ferrari, S. M., Tienghi, A., et al. (2001) · European Journal of Surgical Oncology · doi:10.1053/ejso.2000.1056 · Cited by 45
Seibel, N. L., Krailo, M., Chen, Z., Healey, J. H., Breitfeld, P. P., Drachtman, R. A., Greffe, B. S., Nachman, J. B., Nadel, H. R., Sato, J. K., et al. (2007) · Cancer · doi:10.1002/cncr.22553 · Cited by 44
Kolb, E. A., Gorlick, R. G., Billups, C. A., Hawthorne, T. R., Kurmasheva, R. T., Houghton, P. J., & Smith, M. A. (2014) · Pediatric Blood & Cancer · doi:10.1002/pbc.25099 · Cited by 43
Nataraj, V., Rastogi, S., Khan, S. A., Sharma, M., Agarwala, S., Vishnubhatla, S., & Bakhshi, S. (2016) · Clinical & Translational Oncology · doi:10.1007/s12094-015-1467-8 · Cited by 43
Bacci, G., Briccoli, A., Mercuri, M., Ferrari, S., Bertoni, F., Gasbarrini, A., Fabbri, N., Cesari, M., Forni, C., & Campanacci, M. (1998) · Journal of Chemotherapy · doi:10.1179/joc.1998.10.1.69 · Cited by 42
Novel therapeutic approaches in pediatric and young adult sarcomas
Anderson, P. M., & Pearson, M. G. (2006) · Current Oncology Reports · doi:10.1007/s11912-006-0038-0 · Cited by 42
The Metastasectomy and Timing of Pulmonary Metastases on the Outcome of Osteosarcoma Patients
Huang, Y.-M., Hou, C., Hou, S., & Yang, R. (2009) · Clinical medicine Oncology · doi:10.4137/cmo.s531 · Cited by 40
Fernández‐Pineda, I., Daw, N. C., McCarville, M. B., Emanus, L. J., Rao, B. N., Davidoff, A. M., & Shochat, S. J. (2012) · Journal of Pediatric Surgery · doi:10.1016/j.jpedsurg.2012.03.033 · Cited by 40
Keir, S. T., Morton, C. L., Wu, J., Kurmasheva, R. T., Houghton, P. J., & Smith, M. A. (2011) · Pediatric Blood & Cancer · doi:10.1002/pbc.24016 · Cited by 39
Wolfe, T. D., Pillai, S. P. S., Hildreth, B. E., Lanigan, L. G., Martin, C. K., Werbeck, J. L., & Rosol, T. J. (2011) · Clinical & Experimental Metastasis · doi:10.1007/s10585-011-9377-9 · Cited by 37
Lee, J. A., Paik, E. K., Seo, J., Kim, D. H., Lim, J. S., Yoo, J. Y., & Kim, M. (2015) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyv171 · Cited by 35
Salah, S. H., & Toubasi, S. (2014) · Molecular and Clinical Oncology · doi:10.3892/mco.2014.426 · Cited by 32
Yang, Y., Niu, X., Zhang, Q., Hao, L., Ding, Y., & Xu, H. (2012) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e31823e62e5 · Cited by 23
Picci, P. (2013) · Springer eBooks · doi:10.1007/978-3-319-01748-8_34 · Cited by 23
Is Surgery Warranted for Oligometastatic Disease?
Treasure, T., & Macbeth, F. R. (2015) · Thoracic surgery clinics/Thorac. surg. clin. · doi:10.1016/j.thorsurg.2015.09.010 · Cited by 18
Shen, J. K., Cote, G. M., Choy, E., Hornicek, F. J., & Duan, Z. (2014) · OncoImmunology · doi:10.4161/21624011.2014.954467 · Cited by 15
Phase II study of ifosfamide as a single drug for relapsed paediatric patients
Schwartzman, E., Scopinaro, M. J., & Angueyra, N. (1989) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00253230 · Cited by 14
Cited by
HER-2 Immunohistochemical Expression in Bone Sarcomas: A New Hope for Osteosarcoma Patients
Khalifa, S. E., & Fathy, Y. (2018) · Open Access Macedonian Journal of Medical Sciences · doi:10.3889/oamjms.2018.318 · Cited by 20
Association of circulating tumor cells and IMP3 expression with metastasis of osteosarcoma
Dai, S., Shao, X., Wei, Q., Du, S., Hou, C., Li, H., & Jin, D. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.819357 · Cited by 20
Metadata
- Authors
- Meazza, C., & Scanagatta, P.
- Venue
- Expert Review of Anticancer Therapy
- Publisher
- Informa UK Limited
- Published
- 2016-04-06
- Volume
- 16
- Issue
- 5
- Pages
- 543-556
- ISSN
- 1473-7140 (ISSN-L)
- 1744-8328
- OpenAlex
- W2305290252
- Cited by
- 298
- References
- 112
- FWCI
- 12.18
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.